UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

Journal of clinical oncology, 2013-07, Vol.31 (19), p.2388-2395

2013

Volltextzugriff (PDF)

Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results

Journal of clinical oncology, 2013-07, Vol.31 (19), p.2396-2403

2013

Volltextzugriff (PDF)

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

Journal of clinical oncology, 2013-07, Vol.31 (19), p.2413-2420

2013

Volltextzugriff (PDF)

Carbon honeycomb grids for advanced lead-acid batteries. Part III: Technology scale-up

Journal of power sources, 2015-12, Vol.299, p.324-333

2015

Volltextzugriff (PDF)

Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy

The cancer journal (Sudbury, Mass.), 2010-07, Vol.16 (4), p.399-403

2010

Volltextzugriff (PDF)

GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development

Vaccine, 2007-09, Vol.25, p.B61-B71

2007

Volltextzugriff (PDF)

Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells

Journal of clinical oncology, 2005-12, Vol.23 (35), p.9008-9021

2005

Volltextzugriff (PDF)

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

The lancet oncology, 2018-07, Vol.19 (7), p.916-929

2018

Volltextzugriff (PDF)

Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

Journal of thoracic oncology, 2016-12, Vol.11 (12), p.2208-2217

2016

Volltextzugriff (PDF)

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma

International journal of cancer, 2005-11, Vol.117 (4), p.596-604

2005

Volltextzugriff (PDF)

A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer

Clinical cancer research, 2020-04, Vol.26 (7), p.1725-1735

2020

Volltextzugriff (PDF)

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer

Journal of thoracic oncology, 2015-10, Vol.10 (10), p.1458-1467

2015

Volltextzugriff (PDF)

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)

Annals of oncology, 2016-10, Vol.27 (10), p.1947-1947

2016

Volltextzugriff (PDF)

Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease

Expert opinion on biological therapy, 2008-07, Vol.8 (7), p.951-968

2008

Volltextzugriff (PDF)

Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma

Journal of immunotherapy, 2007-11, Vol.30 (8), p.847-854

2007

Volltextzugriff (PDF)

MAGE-A3-specific anticancer immunotherapy in the clinical practice

Oncoimmunology, 2013-10, Vol.2 (10), p.e25995-e25995

2013

Volltextzugriff (PDF)

The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients

Lung cancer (Amsterdam, Netherlands), 2016-11, Vol.101, p.137-144

2016

Volltextzugriff (PDF)

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

ESMO open, 2016, Vol.1 (4), p.e000068-e000068, Article e000068

2016

Volltextzugriff (PDF)

Cancer regression and neurological toxicity cases after anti-MAGE-A3 TCR gene therapy

Journal of immunotherapy (1997), 2013-02, Vol.36 (2), p.79-81

2013

Volltextzugriff (PDF)

A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene

The Journal of experimental medicine, 1996-03, Vol.183 (3), p.1173-1183

1996

Volltextzugriff (PDF)

Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes

Immunological reviews, 1995-06, Vol.145 (1), p.229-250

1995

Volltextzugriff (PDF)

New tumor antigens recognized by T cells

Current opinion in immunology, 1995-10, Vol.7 (5), p.674-681

1995

Volltextzugriff (PDF)

A tyrosinase nonapeptide presented by HLA‐B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes

European journal of immunology, 1996-01, Vol.26 (1), p.224-230

1996

Volltextzugriff (PDF)

Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus

The Journal of immunology (1950), 1996-11, Vol.157 (9), p.4079-4086

1996

Volltextzugriff (PDF)

A tyrosinase peptide presented by HLA‐B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes

International journal of cancer, 1999-12, Vol.83 (6), p.755-759

1999

Volltextzugriff (PDF)

1 – 25 von 182

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(159)
Mit Volltextzugriff
(140)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

Carbon honeycomb grids for advanced lead-acid batteries. Part III: Technology scale-up

Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy

GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development

Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma

A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)

Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease

Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma

MAGE-A3-specific anticancer immunotherapy in the clinical practice

The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

Cancer regression and neurological toxicity cases after anti-MAGE-A3 TCR gene therapy

A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene

Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes

New tumor antigens recognized by T cells

A tyrosinase nonapeptide presented by HLA‐B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes

Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus

A tyrosinase peptide presented by HLA‐B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes

Suchergebnisse filtern